Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
University of Texas Southwestern Medical Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06881823CT.gov Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC | — | Withdrawn | — | — | — |
NCT07117760CT.gov Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT06145633CT.gov Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06216249CT.gov Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) | — | Recruiting | — | — | — |
NCT06288113CT.gov Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial | — | Recruiting | — | — | — |
NCT06200103CT.gov Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06462508CT.gov Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis | — | Recruiting | — | — | — |
NCT06437496CT.gov 68Ga-AAZTA-093 PET/CT: First-in-human Study | — | Unknown | — | — | — |
NCT06067269CT.gov Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | — | Recruiting | — | — | — |
NCT05034562CT.gov Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | — | Withdrawn | — | — | — |
Show 25 more trialsShow fewer
NCT05547386CT.gov 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT05324332CT.gov 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients | — | Recruiting | — | — | — |
NCT04976257CT.gov Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion | — | Completed | — | — | — |
NCT05744115CT.gov Ga-68-PSMA-11 in Men With Prostate Cancer | — | Terminated | — | — | — |
NCT04886986CT.gov Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04777071CT.gov An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04402151CT.gov Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer | — | Recruiting | — | — | — |
NCT04279561CT.gov Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03822871CT.gov A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03768349CT.gov PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer | — | Completed | — | — | — |
NCT03803475CT.gov Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients | — | Completed | — | — | — |
NCT03545165CT.gov 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC | — | Terminated | — | — | — |
NCT04050215CT.gov 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | — | Completed | — | — | — |
NCT03388346CT.gov 68Ga PSMA in Preprostatectomy Patients | — | Completed | — | — | — |
NCT03389451CT.gov 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer | — | Completed | — | — | — |
NCT03362359CT.gov Ga-68-PSMA-11 in High-risk Prostate Cancer | — | Completed | — | — | — |
NCT03353740CT.gov Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence | — | Completed | — | — | — |
NCT03187990CT.gov Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA | — | Completed | — | — | — |
NCT03675451CT.gov PSMA Imaging of Localized Prostate Cancer | — | Completed | — | — | — |
NCT03042468CT.gov Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC | — | Active Not Recruiting | — | — | — |
NCT02919111CT.gov Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients | — | Completed | — | — | — |
NCT02918357CT.gov Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | — | Completed | — | — | — |
NCT02659527CT.gov PET/MRI in Patients With Suspected Prostate Cancer | — | Completed | — | — | — |
NCT02611882CT.gov Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients | — | Completed | — | — | — |
NCT04452136CT.gov Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gozetotide (this asset) | University of Texas Southwestern Medical Center | P3 | BB · 66 |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BBB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BBB |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BB |
| Goserelin | Bayer | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Flutamide | VA Office of Research and Development | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Gozetotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P3 | BB · 68 |
| Metastatic Prostate Carcinoma | — | Unk | C · 35 |
| Prostate Disorder | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gozetotide in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/gozetotide-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →